MiNK Therapeutics’ (INKT) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of MiNK Therapeutics (NASDAQ:INKT) in a report published on Wednesday,Benzinga reports. The firm currently has a $35.00 target price on the stock.

Separately, Wall Street Zen raised MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $35.00.

MiNK Therapeutics Price Performance

Shares of NASDAQ:INKT opened at $10.57 on Wednesday. MiNK Therapeutics has a 1-year low of $6.34 and a 1-year high of $76.00. The stock has a market cap of $49.57 million, a P/E ratio of -3.56 and a beta of 0.35. The firm has a fifty day moving average price of $10.92 and a 200 day moving average price of $12.23.

MiNK Therapeutics (NASDAQ:INKT) last announced its earnings results on Tuesday, March 31st. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.68) by $0.14. Sell-side analysts expect that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

Institutional Investors Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC grew its stake in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,247 shares of the company’s stock after purchasing an additional 1,441 shares during the period. Geode Capital Management LLC owned approximately 0.30% of MiNK Therapeutics worth $159,000 at the end of the most recent reporting period. 2.87% of the stock is owned by institutional investors and hedge funds.

About MiNK Therapeutics

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.